^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | 225Ac-FL-020 (Ionizing radiation emitter, PSMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published date:
07/02/2024
Excerpt:
Full-Life Technologies...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 225Ac-FL-020, the company's lead radiopharmaceutical, which targets prostate-specific membrane antigen (PSMA), for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
